BGI Genomics announces that its Monkeypox Virus Nucleic Acid Detection Kit (Fluorescent PCR) has recently obtained CE-IVDD approval.

This kit adopts the fluorescence PCR method to detect the MPV-1 gene and MPV-2 gene fragment of the Monkeypox virus (MPV).

The detection kit is a clinical diagnosis aid to detect suspected cases of MPV infection. Rash fluid, nasopharyngeal swabs, pharyngeal swabs, and serum samples are applicable for the test. The test result is available in 40 minutes after collecting samples.

Monkeypox is an acute zoonotic infectious disease caused by MPV. The disease is mainly transmitted by animals but can also be transmitted between people, through respiratory droplets during prolonged, face-to-face contact, contact with patient body fluids, or contaminated objects.

The clinical symptoms of MPV infection in humans are similar to smallpox. Generally, after a 6 to 13-day incubation period, symptoms such as fever, headache, muscle and back pain, fatigue, and rash would appear.

About BGI Genomics 

BGI Genomics, headquartered in Shenzhen China, is the world’s leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.